Atossa Therapeutics reports FY2022 net loss of $26.96M; provides clinical updates on (Z)-endoxifen trials

ATOSSA THERAPEUTICS, INC.

Net loss of $26.96M ($0.21 diluted EPS) vs $20.6M loss in FY2021; operating expenses up 35% to $27.7M.
R&D expenses rose 64% to $15.1M, driven by clinical trials for (Z)-endoxifen and AT-H201 programs.
Cash, cash equivalents and restricted cash totaled $111M as of Dec 31, 2022, down from $136.5M a year earlier.
Initiated Phase 2 EVANGELINE study for (Z)-endoxifen in ER+/HER2- breast cancer; first patient dosed.
Invested $4.7M in Dynamic Cell Therapies, acquiring ~19% stake; new patent granted for enteric capsule formulation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for the fiscal year ended December 31, 2022.

Period: the fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 22, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2022 financial results and a Company update.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-007529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.